The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
May 16th 2024
This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
June 27, 2024 | 1:00 PM & 7:00 PM ET
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Study Finds Potential Biomarkers for Cognitive Decline in MS Over 5-Year Period
August 16th 2021Investigators found that biomarkers for neurodegeneration and inflammation could also aid providers in detecting declines in cognition and information processing speed in patients with multiple sclerosis (MS) over a 5-year period.
Read More
Single-Leg Heel Test May Be Useful Tool for Differentiating Limb Strength in MS
August 12th 2021The single-leg heel test was able to differentiate between weaker and stronger limbs in patients with multiple sclerosis (MS) and in healthy controls, suggesting that the test could prove useful for identifying impaired muscle performance.
Read More
Diagnose, Monitor, Treat: How AI’s 3-Pronged Approach Can Help to Propel Progress in MS
August 5th 2021Using artificial intelligence (AI) effectively may help to revolutionize the diagnosis, monitoring, and treatment of multiple sclerosis (MS), as well as optimizing understanding of the immune-mediated disease.
Read More
High Efficacy Therapies in MS: Ocrelizumab, Ofatumumab, and Cladribine
Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.
Watch
Greater DMT Adherence Linked With Superior Outcomes Among Veterans With MS
July 14th 2021Results of a retrospective observational study indicate good adherence to disease-modifying therapies (DMTs) for multiple sclerosis (MS) is associated with better outcomes among veterans with the disease.
Read More
Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
Watch
Study Offers New Tools to Differentiate Between MS, Neuromyelitis Optica Spectrum Disorder
June 25th 2021Although existing research has shown structural differences between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.
Read More
Early Intensive DMT Use May Prevent Greater Long-term Disability in RRMS
June 22nd 2021Early intensive treatment was more efficacious at slowing disease accumulation in patients with relapsing-remitting multiple sclerosis (RRMS) vs initiating therapy with a moderate-efficacy disease-modifying treatment (DMT) prior to switching to a higher-efficacy DMT.
Read More